Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo

International Journal of Cancer

Volumn 92, Issue 5, 2001, Pages 718-724

  Burger, Angelika M ^b   Hartung, Gernot ^b   Stehle, Gerd ^b   Sinn, Hannsjrg ^c   Fiebig, Heinz Herbert ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Anti tumor activity; Human tumor xenografts; Maximal tolerated dose; Methotrexate; Methotrexate human serum albunmin; Tumor growth inhibition; Vascular permeability

Indexed keywords

HUMAN SERUM ALBUMIN; METHOTREXATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG UPTAKE; HUMAN; IN VIVO STUDY; LUNG CANCER; MACROMOLECULE; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SOFT TISSUE SARCOMA; SOLID TUMOR; TUMOR XENOGRAFT;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG EVALUATION; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; METHOTREXATE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PROSTATIC NEOPLASMS; SARCOMA; SERUM ALBUMIN; TRANSPLANTATION, HETEROLOGOUS;

EID: 0035371902     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20010601)92:5<718::AID-IJC1257>3.0.CO;2-D     Document Type: Article

References (38)

1. Analogs of pteroyl glutamic acid. III. 4-Amino derivatives
2. Five years experience with the chemotherapy of metastatic choriocarcinoma and related trophoblastic tumors in women
3. Ode to methotrexate
4. New antimetabolites in cancer chemotherapy and their clinical impact
5. Anticancer drugs
6. Methotrexate
7. On the growth rates of human malignant tumors: Implications for medical decision making
8. Vascular and interstitial barriers to delivery of therapeutic agents in tumors
9. Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinosarcoma
10. Methotrexate-albumin conjugate causes tumor growth delay in Dunning R3327 Hi prostate cancer bearing rats
11. Identification of tissue sites for increased albumin degradation in sarcoma-bearing mice
12. Plasma protein (albumin) catabolism by the tumor itself-implications for tumor metabolism and the genesis of cachexia
13. Serum albumin (SA) accumulation by bronchogenic tumours: A tracer technique may help with patient selection for SA-delivered chemotherapy
14. Enhanced albumin uptake by rat tumors
15. Transport d'agents cytostatiques par les protéines plasmatiques: III. Activité antitumorale in vitro de conjugués cytostatique-azoprotéines
16. Some biochemical and pharmacologic properties of amethopterin-albumin
17. High molecular weight derivatives of methotrexate as chemotherapeutic agents
18. Characterization of in-vitro drug release and biological activity of methotrexate-bovine serum albumin conjugates
19. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. V. Alternative method for preparation of serum albumin-methotrexate derivative
20. The loading rate determines tumor targeting of methotrexate-albumin conjugates in rats
21. Pharmacokinetics of methotrexate-albumin conjugates in tumor bearing rats
22. Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. PART I
23. Combined in vitro/in vivo testing procedures with human tumor xenografts for new drug development
24. Human tumor xenografts: Predictivity, characterization and discovery of new anticancer agents
25. United Kingdom Co-Ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasy
26. Protocols for screening chemical agents and natural products against tumor and other biological systems
27. Vascular reactions to histamine, histamine liberator and leukotaxine in the skin of guinea pigs
28. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs
29. Activity of free and carrier-bound methotrexate against transport-deficient and highly dihydrofolate dehydrogenase-containing methotrexate-resistant L 1210 cells
30. Distribution patterns of radiolabeled human, bovine, and rat albumins in tumor bearing rats
31. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics
32. Quantitative relationship between toxic doses of antitumor chemotherapeutic agents in animals and men
33. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients
34. Development of human tumor models for evaluation of compounds which target tumor vasculature
35. Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1
36. Doxorubicin-polymer conjugates: Further demonstration of the concept of enhanced permeability and retention
37. Phase I clinical and pharmacokinetic study of PK1 (HPMA copolymer doxorubicin): First member of a new class of chemotherapeutic agents - Drug polymer conjugates